SEC 13F Intelligence

Managers / Q4 2021 · view latest →

Canaan Partners X LLC

CIK 0001673228 · 2765 SAND HILL ROAD, MENLO PARK, CA, 94025 · 6508548092

Reported Value
$257M
Q4 2021
Positions
4
Filings on Record
16
2019–present window
Filed
Feb 3, 2022
original filing

Summary

Canaan Partners X LLC reported $257M in U.S.-listed holdings across 4 positions for Q4 2021.

The portfolio is heavily concentrated: Astra Space alone accounts for 44.5% of reported value.

Compared with Q3 2021, the fund opened 0 new positions and exited 1.

Portfolio Metrics

Turnover
0.0%
vs prior filed quarter
Largest Position
+44.5%
Astra Space

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’19: $155MQ4 ’19Q1 ’20: $91MQ2 ’20: $83MQ2 ’20Q3 ’20: $50MQ4 ’20: $48MQ4 ’20Q1 ’21: $73MQ2 ’21: $67MQ2 ’21Q3 ’21: $351MQ4 ’21: $257MQ4 ’21Q1 ’22: $98MQ2 ’22: $58MQ2 ’22Q3 ’22: $64MQ4 ’22: $57MQ4 ’22Q1 ’23: $56MQ2 ’23: $84MQ2 ’23Q3 ’23: $75Mfilingsflow.com

Portfolio Composition

By security type
Other: 75.5%Common Stock: 24.5%
  • Other · 75.5% · $194M
  • Common Stock · 24.5% · $63M

Quarter-over-Quarter Changes full breakdown →

vs Q3 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
NextCure IncSOLD OUT321.6K0$2M$0
Astra Space IncTRIMMED4.20M16.49M$66M$114M
Berkshire Grey IncHELD+014.30M$22M$79M
IDYAIDEAYA Biosciences IncHELD+02.66M$5M$63M
Iterum Therapeutics plcHELD+01.73M$288,000$679,000

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q4 2021

4 positions
#IssuerClass% PortfolioValueShares
1Astra Space IncCOM CL A44.55%$114M16.49M
2Berkshire Grey IncCOM CL A30.67%$79M14.30M
3IDYAIDEAYA Biosciences Inchistory →COM24.52%$63M2.66M
4Iterum Therapeutics plcSHS0.26%$679,0001.73M

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q3 2023$75M2Oct 11, 202313F-HRchanges · EDGAR ↗
Q2 2023$84M3Jul 13, 202313F-HRchanges · EDGAR ↗
Q1 2023$56M2Apr 6, 202313F-HRchanges · EDGAR ↗
Q4 2022$57M2Feb 1, 202313F-HRchanges · EDGAR ↗
Q3 2022$64M3Oct 31, 202213F-HRchanges · EDGAR ↗
Q2 2022$58M4Aug 10, 202213F-HRchanges · EDGAR ↗
Q1 2022$98M4Apr 28, 202213F-HRchanges · EDGAR ↗
Q4 2021$257M4Feb 3, 202213F-HRchanges · EDGAR ↗
Q3 2021$351M5Nov 15, 202113F-HRchanges · EDGAR ↗
Q2 2021$67M3Jul 22, 202113F-HRchanges · EDGAR ↗
Q1 2021$73M3May 3, 202113F-HRchanges · EDGAR ↗
Q4 2020$48M3Feb 2, 202113F-HRchanges · EDGAR ↗
Q3 2020$50M3Oct 26, 202013F-HRchanges · EDGAR ↗
Q2 2020$83M3Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$91M3May 11, 202013F-HRchanges · EDGAR ↗
Q4 2019$155M3Jan 27, 202013F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.